BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Helicobacter Pylori Diagnostics industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

Growing burden of cancer, rising demand for personalized medicine, and increasing collaborations to co-develop drug and diagnostic technologies are key factors driving market growth.

The industry analysis report is considered a valuable source of information about the global Particle Therapy Systems industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The global lyme disease treatment market size is expected to hit around US$ 3 billion by 2030 from at US$ 1.6 billion in 2020, expanding growth at a CAGR of 5.9% from 2021 to 2030.

Children with Dravet syndrome, a severe form of epilepsy that begins in infancy, experience seizures, usually for their entire life.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its first quarter 2022 financial results on Wednesday, May 11, 2022.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2™ insulin pump with Control-IQ® advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes, and user-reported reduced burden of diabetes management.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2021 on Wednesday, May 4 at 9 a.m., ET.

Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022.